Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Design Example: Alignment of a Road Line Using GIS01:17

Design Example: Alignment of a Road Line Using GIS

339
The alignment of a road line using Geographic Information Systems (GIS) is a critical process in civil engineering, combining advanced technology with practical decision-making. This methodology begins with the collection of geospatial data, including information on land cover, geomorphology, drainage patterns, slope, and contour details. Such data is typically acquired through satellite imagery and GIS tools, offering a comprehensive understanding of the terrain.Once the data is gathered, it...
339
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

867
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
867
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

1.8K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
1.8K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

4.0K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.0K
Adrenergic Agonists: Therapeutic Classification01:18

Adrenergic Agonists: Therapeutic Classification

1.5K
Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
1.5K
Direct-Acting Cholinergic Agonists: Pharmacokinetics01:31

Direct-Acting Cholinergic Agonists: Pharmacokinetics

1.8K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Role of EP3 Agonism in Intraocular Pressure-Lowering by Sepetaprost, a Novel Dual Agonist of FP and EP3 Receptors, in Monkeys.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics·2025
Same author

Re: Di Staso and Gaudio-Aqueous Outflow Facility after Periocular Triamcinolone Injection: A Preliminary Evaluation of the Falck Medical Applanation Tonometer.

Journal of current glaucoma practice·2025
Same author

Effects of Growth and Development on Aqueous Humor Dynamics in Male Dutch Belted Rabbits.

Investigative ophthalmology & visual science·2025
Same author

Aqueous Humor Dynamics Changes and Predictors of IOP Response to Latanoprost in Healthy Subjects.

Journal of glaucoma·2025
Same author

Segmental Uveoscleral Outflow and its Relationship With Trabecular Outflow in Monkey Eyes.

Investigative ophthalmology & visual science·2025
Same author

Understanding Individual Intraocular Pressure Response to Treatment with Latanoprost and Timolol.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics·2025

Related Experiment Video

Updated: Jan 21, 2026

Using Affordable LED Arrays for Photo-Stimulation of Neurons
07:40

Using Affordable LED Arrays for Photo-Stimulation of Neurons

Published on: November 15, 2011

19.0K

Antiglaucoma EP2 Agonists: A Long Road That Led Somewhere.

David F Woodward1,2, Jenny W Wang2, W Daniel Stamer3

  • 1Department of Bioengineering, Imperial College London, London, United Kingdom.

Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|July 23, 2019
PubMed
Summary

EP2 agonists, a class of antiglaucoma drugs, have been researched for over 20 years. The first drug in this class is now approved, marking a significant advancement in glaucoma treatment.

Keywords:
EP2 agonistsdrug deliveryglaucoma therapy

More Related Videos

Quantifying Agonist Activity at G Protein-coupled Receptors
11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

19.8K
LED Thermo Flow — Combining Optogenetics with Flow Cytometry
05:49

LED Thermo Flow — Combining Optogenetics with Flow Cytometry

Published on: December 30, 2016

8.9K

Related Experiment Videos

Last Updated: Jan 21, 2026

Using Affordable LED Arrays for Photo-Stimulation of Neurons
07:40

Using Affordable LED Arrays for Photo-Stimulation of Neurons

Published on: November 15, 2011

19.0K
Quantifying Agonist Activity at G Protein-coupled Receptors
11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

19.8K
LED Thermo Flow — Combining Optogenetics with Flow Cytometry
05:49

LED Thermo Flow — Combining Optogenetics with Flow Cytometry

Published on: December 30, 2016

8.9K

Area of Science:

  • Ophthalmology and Pharmacology
  • Drug Discovery and Development

Background:

  • Glaucoma treatment research has focused on EP2 agonists for over two decades.
  • Significant scientific efforts have been invested globally by both academic and industrial researchers.

Purpose of the Study:

  • To review the comprehensive development of EP2 agonists for glaucoma.
  • To cover the journey from initial concept to clinical approval.

Main Methods:

  • Review of scientific literature and drug development data.
  • Analysis of pharmacological properties, structure-activity relationships, and biodistribution.
  • Examination of therapeutic applications and drug delivery systems.

Main Results:

  • The development pipeline for EP2 agonists has culminated in the recent approval of the first drug in this class.
  • Extensive research has elucidated the pharmacology, structure, and delivery of these compounds.

Conclusions:

  • EP2 agonists represent a significant therapeutic advancement in antiglaucoma treatment.
  • The successful development highlights the potential of targeted drug discovery in ophthalmology.